COVID-19 Clinical Trial
— COVID-19-HBOOfficial title:
A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19
Verified date | January 2023 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure. We explore a treatment administered in a randomized clinical trial that could prevent ICU admission and reduce mortality. The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the inflammatory response.
Status | Terminated |
Enrollment | 34 |
Est. completion date | December 1, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion criteria: 1. Aged 18-90 years 2. PaO2/FiO2 (PFI) below 200 mmHg (26.7 kPa) 3. Suspected or verified SARS-CoV-2 infection 4. At least two risk factors for increased morbidity/mortality - Age above 50 years - Hypertension - Cardiovascular disease - Diabetes or pre-diabetes - Active or cured cancer - Asthma/COPD - Smoking - D-Dimer > 1.0 mg/L - Auto-immune disease 5. Documented informed consent according to ICH-GCP and national regulations Exclusion Criteria: 1. ARDS/pneumonia caused by other viral infections (positive for other virus) 2. ARDS/pneumonia caused by other non-viral infections or trauma 3. Known pregnancy or positive pregnancy test in women of childbearing age 4. Patients with previous lung fibrosis more than 10% 5. CT- or Spirometry-verified severe COPD with Emphysema 6. Contraindication for HBO according to local guidelines 7. Not likely to need ICU admission < 7 days of screening (Subjective criteria that may exclude any patients that fulfil the other inclusion criteria but where the treating physician suspect a spontaneous recovery) 8. Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation 9. Prisoner (Exclusion criteria according to IRB at UCSD) |
Country | Name | City | State |
---|---|---|---|
Germany | Krankenhaus St. Joesf | Regensburg | |
Sweden | Blekingesjukhuset | Karlskrona | Blekinge |
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Blekinge County Council Hospital, JK Biostatistics AB, Karolinska Trial Alliance, The Swedish Research Council, University of California, San Diego, University of Regensburg |
Germany, Sweden,
Gorenstein SA, Castellano ML, Slone ES, Gillette B, Liu H, Alsamarraie C, Jacobson AM, Wall SP, Adhikari S, Swartz JL, McMullen JJS, Osorio M, Koziatek CA, Lee DC. Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls. Undersea Hyperb Med. 2020 Third Quarter;47(3):405-413. doi: 10.22462/01.03.2020.1. — View Citation
Kjellberg A, De Maio A, Lindholm P. Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19? Med Hypotheses. 2020 Nov;144:110224. doi: 10.1016/j.mehy.2020.110224. Epub 2020 Aug 30. — View Citation
Oscarsson N, Muller B, Rosen A, Lodding P, Molne J, Giglio D, Hjelle KM, Vaagbo G, Hyldegaard O, Vangedal M, Salling L, Kjellberg A, Lind F, Ettala O, Arola O, Seeman-Lodding H. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019 Nov;20(11):1602-1614. doi: 10.1016/S1470-2045(19)30494-2. Epub 2019 Sep 16. Erratum In: Lancet Oncol. 2019 Sep 23;: — View Citation
Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020 May 1;29(Sup5a):S4-S8. doi: 10.12968/jowc.2020.29.Sup5a.S4. — View Citation
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hospital mortality | Hospital mortality of any cause, proportion of subjects, from day 1 to day 30. | Through study completion 30 days | |
Other | ICU mortality | Proportion of subjects with ICU mortality, Mortality of any cause in ICU, from day 1 to day 30. | From ICU admission to study completion 30 days | |
Other | Time in Invasive Ventilation | Time-to-stop of intubation/invasive mechanical ventilation, from ICU admission to day 30. | From ICU admission to study completion 30 days | |
Other | NEWS | Mean daily NEWS from day 1 to day 30. | Through study completion 30 days | |
Other | PaO2/FiO2 (PFI) | Mean change in PaO2/FiO2 (PFI), from day 1 to day 2, … to day 30. | Through study completion 30 days | |
Other | HBO Compliance | Proportion of HBO treatments given vs planned.
Proportion of subjects with HBO treatment administered within 24h after enrolment. |
Day 1 to day 7 | |
Other | Hospital discharge | Time-to-discharge from hospital | Through study completion 30 days | |
Other | Oxygen dose | Mean oxygen dose per day including HBO and cumulative pulmonary oxygen toxicity expressed as Units of oxygen pulmonary toxicity dose (UPTD) and Cumulative pulmonary toxicity dose (CPTD) from day 1 to day 30. | Through study completion 30 days | |
Other | HBO dose | Median number of HBO treatments and dose of HBO given, from day 1 to day 7 | Day 1 to day 7 | |
Other | Micro RNA | Change in expression of Micro RNA in plasma from day 1 to day 30 | Through study completion 30 days | |
Other | Hypoxic response | Change in gene expression and Micro RNA interactions in Peripheral Blood Mononuclear Cells (PBMC) (20 Subjects) from day 1 to day 30 | Through study completion 30 days | |
Other | Immunological response | Immunological response (20 subjects) from day 1 to day 30 in the following.
Cytokines extended including (IL-1ß, IL-2, IL-6, IL33 and TNFa) Lymphocyte profile Flowcytometry with identification of monocyte/lymphocyte subsets including but not limited to CD3+/CD4+/CD8+ and CD4+/CD8+ ratio FITMaN panel/Flow cytometry, Interleukins (IL-1ß, IL-2, IL-6, IL33 and TNFa), T-reg cells (CD3+/CD4+/CD25+/CD127+) Monocyte proliferation markers, Ex vivo monocyte function |
Through study completion 30 days | |
Other | Multi organ dysfunction | Mean change in routine biomarkers for organ dysfunction, from day 1to day 30. | Through study completion 30 days | |
Other | Viral load | Viral load, review of records from day 1 to day 30. | Through study completion 30 days | |
Other | Secondary infections | Number of secondary infections, review of records, number of events and patients from day 1 to day 30. | Through study completion 30 days | |
Other | Pulmonary embolism | Diagnosed PE needing treatment, review of records, number of events and patients from day 1 to day 30. | Through study completion 30 days | |
Other | Pulmonary CT | Changes on Pulmonary CT, review of records from day 1 to day 30. | Through study completion 30 days | |
Other | Chest X-ray | Changes on Chest X-ray, review of records from day 1 to day 30. | Through study completion 30 days | |
Other | Lung ultrasound | Changes in Lung ultrasound, review of records from day 1 to day 30. | Through study completion 30 days | |
Primary | ICU admission | The proportion of subjects admitted to ICU from day 1 to day 30, based on at least one of the following criteria:
i) Rapid progression over hours ii) Lack of improvement on high flow oxygen >40L/min or non invasive ventilation with fraction of inspired oxygen (FiO2) > 0.6 iii) Evolving Hypercapnia or increased work of breathing not responding to increased oxygen despite maximum standard of care available outside ICU iv) Hemodynamic instability or multi organ failure with maximum standard of care available outside ICU |
Through study completion 30 days | |
Secondary | 30-day mortality | Proportion of subjects with 30-day mortality, all cause Mortality, from day 1 to day 30. | Through study completion 30 days | |
Secondary | Time-to-intubation | Time-to-Intubation, i.e. cumulative days free of invasive mechanical ventilation, from day 1 to day 30 | Through study completion 30 days | |
Secondary | Time-to-ICU | Time-to-ICU, i.e. cumulative ICU free days, derived as the number of days from day 1 to ICU, where all ICU free subjects are censored at day 30. | Through study completion 30 days | |
Secondary | Inflammatory response | Mean change in inflammatory response from day 1 to day 30.
White cell count + differentiation Procalcitonin C-Reactive protein Cytokines (IL-6) (if available at local laboratory) Ferritin D-Dimer LDH |
Through study completion 30 days | |
Secondary | Overall survival | Overall survival (Kaplan-Meier) | Through study completion 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|